These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP),
representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the …

This guideline is the result of a consensus reached during a panel discussion at the second
International Consensus Meeting on Urticara, Urticaria 2004, a joint initiative of the EAACI …

This guideline, together with its sister guideline on the classification of urticaria (Zuberbier T,
Asero R, Bindslev‐Jensen C, Canonica GW, Church MK, Giménez‐Arnau AM et al …

Chronic urticaria is a disease that can significantly impact a patient's quality of life and ability
to function. There are effective treatment options, such as non-sedating antihistamines or …

Background Delayed pressure urticaria (DPU) is characterized by recurrent erythematous
and often painful swelling after the skin is exposed to sustained pressure. Treatment is …

Background Short courses of adjunctive systemic corticosteroids are commonly used to treat
acute urticaria and chronic urticaria flares (both with or without mast cell-mediated …

Background Delayed pressure urticaria (DPU) comes under the heading of physical
urticaria. Characteristically itchy, tender or painful weals occur at sites of local pressure …

Abstract Background: Chronic urticaria (CU), characterized by≥ 6 weeks of intense pruritus,
remains a debilitating condition for patients. New and safe treatments are needed to …

Delayed pressure urticaria (DPU) is a type of physical urticaria characterized by the gradual
onset of wheals or edema in areas where pressure has been applied to the skin. Usually …

Ketotifen is an oral antiallergic drug developed in 1970 by Sandoz Pharmaceuticals of
Switzerland. It is a benzocycloheptathiophene derivative and was initially marketed as an …